Insights from the 8th Zhenghe International Functional Medicine Innovation Conference
As China accelerates the implementation of the Healthy China 2030 blueprint, chronic disease prevention and early intervention have become central to the national health agenda.
Non-communicable diseases (NCDs), including cardiovascular disease, diabetes and certain cancers, remain the leading causes of mortality in China. Public health authorities have noted a concerning trend: the age of onset for several chronic conditions is gradually decreasing. Against this backdrop, policymakers and medical professionals are seeking more proactive approaches to risk management, aiming to shift from reactive treatment toward early-stage prevention.
Recent discussions at the 8th Zhenghe International Functional Medicine Innovation Conference reflected this broader transition in healthcare philosophy.
From Disease Treatment to Risk Management
Globally, preventive medicine is undergoing a conceptual shift. Increasingly, experts emphasize that chronic diseases are not sudden events but the result of long-term biological and metabolic risk accumulation.
Some scholars have described this evolution as a move toward “Health 3.0” — a framework that prioritizes long-term risk assessment, biomarker monitoring and personalized lifestyle optimization. The approach seeks to flatten the future risk curve of major diseases rather than simply managing symptoms after diagnosis.
This transition aligns with China’s policy direction of advancing early screening, improving health literacy and strengthening integrated chronic disease management.
Blood Microenvironment as an Emerging Research Perspective
Among the themes discussed at the conference was the role of the blood microenvironment in chronic disease risk assessment.
Blood is not only responsible for oxygen and nutrient transport, but also carries inflammatory mediators, metabolic signaling molecules and immune regulators. Growing evidence suggests that low-grade chronic inflammation, metabolic imbalance and endothelial dysfunction may precede clinically detectable disease.
Professor Zhao Shuming — a senior visiting scholar at the US Centers for Disease Control and Prevention (CDC), postdoctoral researcher at Emory University and vice president of the Asia-Pacific Blood Type and Genomics Association — noted that monitoring changes in the blood microenvironment may offer an earlier window into disease risk.
- Chief Physician、Professor、Doctoral Supervisor
- Hunt Health – Chief Expert in the Clinical Application and Research of Ozone Therapy
- Senior Visiting Scholar of the US CDC
- Postdoctoral Fellow of Emory University (US)
- Vice President of the International Asia-Pacific Association of Blood Group and Genomics
Some researchers refer to this line of inquiry as “blood-based anti-aging” or blood microenvironment management. However, experts emphasize that the concept does not aim to reverse chronological aging. Rather, it focuses on optimizing internal physiological balance — including inflammatory status, metabolic stability and circulatory function — with the goal of extending healthspan, the period of life spent in good health.
Addressing the Challenge of Earlier-Onset Chronic Disease
Chronic diseases typically develop over many years before symptoms become apparent. By the time clinical diagnosis occurs, biological risk may have accumulated for a decade or longer.
In this context, integrating multi-dimensional biomarker assessment — including blood-related indicators — into preventive health strategies may contribute to earlier risk identification. Such efforts complement broader public health initiatives that encourage healthier lifestyles, improved nutrition, physical activity and regular screening.
Experts caution, however, that any emerging approach must be grounded in evidence-based medicine and subject to appropriate regulatory oversight.
Balancing Innovation with Scientific Rigor
While interest in risk-oriented health management continues to grow, medical professionals stress the importance of scientific validation and careful implementation.
They underline several key principles:
- Continued accumulation of high-quality clinical evidence
- Transparent regulatory frameworks
- Avoidance of over-medicalization
- Clear distinction between scientific research and commercial promotion
Chronic disease prevention remains a long-term, systemic endeavor requiring coordinated efforts from policymakers, researchers and healthcare providers.
From Lifespan to Healthspan
As global populations age, the conversation around healthcare is shifting from simply prolonging life to enhancing the quality of those added years.
China’s ongoing public health reforms reflect this transformation. Explorations into blood microenvironment research represent one of several avenues being examined within the broader movement toward earlier risk management and preventive care.
Under the Healthy China 2030 vision, advancing front-loaded chronic disease prevention — while maintaining scientific rigor and regulatory prudence — will remain a central objective in the years ahead.
